160 related articles for article (PubMed ID: 25059786)
1. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors.
Kauffmann RM; Wang L; Phillips S; Idrees K; Merchant NB; Parikh AA
Ann Surg Oncol; 2014 Oct; 21(11):3422-8. PubMed ID: 25059786
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas.
Kamp K; Damhuis RA; Feelders RA; de Herder WW
Endocr Relat Cancer; 2012 Feb; 19(1):95-9. PubMed ID: 22194442
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours.
Clift AK; Drymousis P; Al-Nahhas A; Wasan H; Martin J; Holm S; Frilling A
Neuroendocrinology; 2015; 102(1-2):26-32. PubMed ID: 25824138
[TBL] [Abstract][Full Text] [Related]
4. Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study.
Murphy JD; Ma GL; Baumgartner JM; Madlensky L; Burgoyne AM; Tang CM; Martinez ME; Sicklick JK
Cancer; 2015 Sep; 121(17):2960-7. PubMed ID: 25930983
[TBL] [Abstract][Full Text] [Related]
5. The impact of additional malignancies in patients diagnosed with gastrointestinal stromal tumors.
Smith MJ; Smith HG; Mahar AL; Law C; Ko YJ
Int J Cancer; 2016 Oct; 139(8):1744-51. PubMed ID: 27299364
[TBL] [Abstract][Full Text] [Related]
6. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
7. The Risk of Second Primary Malignancies in Patients With Lung Neuroendocrine Tumors: A Population-Based Study on SEER Database.
Bu X; Wang X; Wei L; Liu J; Chen M
Curr Probl Cancer; 2020 Dec; 44(6):100613. PubMed ID: 32563531
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of neuroendocrine tumours.
Taal BG; Visser O
Neuroendocrinology; 2004; 80 Suppl 1():3-7. PubMed ID: 15477707
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
Pape UF; Berndt U; Müller-Nordhorn J; Böhmig M; Roll S; Koch M; Willich SN; Wiedenmann B
Endocr Relat Cancer; 2008 Dec; 15(4):1083-97. PubMed ID: 18603570
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine tumors and second primary malignancy--a relationship with clinical impact?
Prommegger R; Ensinger C; Steiner P; Sauper T; Profanter C; Margreiter R
Anticancer Res; 2004; 24(2C):1049-51. PubMed ID: 15154621
[TBL] [Abstract][Full Text] [Related]
11. The epidemiology of gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409
[TBL] [Abstract][Full Text] [Related]
12. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
13. Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population-based study.
Cai W; Tan Y; Ge W; Ding K; Hu H
Cancer Med; 2018 Jun; 7(6):2699-2709. PubMed ID: 29733523
[TBL] [Abstract][Full Text] [Related]
14. Risk of Primary Neuroendocrine Pancreatic Tumor After a First Primary Cancer: A US Population-Based Study.
Kamath GR; Kim MK; Taioli E
Pancreas; 2019 Feb; 48(2):161-168. PubMed ID: 30589832
[TBL] [Abstract][Full Text] [Related]
15. Pediatric solid tumors and second malignancies: characteristics and survival outcomes.
Vasudevan V; Cheung MC; Yang R; Zhuge Y; Fischer AC; Koniaris LG; Sola JE
J Surg Res; 2010 May; 160(2):184-9. PubMed ID: 19765728
[TBL] [Abstract][Full Text] [Related]
16. The risk of bladder cancer in patients diagnosed with other primary neoplasms: analysis of the SEER database.
Anderson JK; Alanee S; Lindgren B; Slaton J
Urol Oncol; 2013 Aug; 31(6):862-5. PubMed ID: 21784673
[TBL] [Abstract][Full Text] [Related]
17. Second Primary Malignancy in Bladder Carcinoma - A Population-based Study.
Khanal A; Budhathoki N; Singh VP; Shah BK
Anticancer Res; 2017 Apr; 37(4):2033-2036. PubMed ID: 28373478
[TBL] [Abstract][Full Text] [Related]
18. Extrapancreatic malignancies in patients with pancreatic cancer: epidemiology and clinical consequences.
Hackert T; Tjaden C; Müller S; Hinz U; Hartwig W; Strobel O; Fritz S; Schmied B; Büchler MW; Werner J
Pancreas; 2012 Mar; 41(2):212-7. PubMed ID: 21934549
[TBL] [Abstract][Full Text] [Related]
19. Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry.
Rihani R; Bazzeh F; Faqih N; Sultan I
Cancer; 2010 Sep; 116(18):4385-94. PubMed ID: 20549819
[TBL] [Abstract][Full Text] [Related]
20. Increased risk and pattern of secondary malignancies in patients with invasive extramammary Paget disease.
Karam A; Dorigo O
Br J Dermatol; 2014 Mar; 170(3):661-71. PubMed ID: 24617434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
